The drug, which Lilly in-licensed four years ago and is designed to inhibit a protein known as P2X7, did not meet the company ...
There are three obstacles to faster development and deployment of non-addictive pain treatments. They are the business ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback